Skip to main content

Signed · United Kingdom · Pharma and biotech

Merck KGaA agrees to acquire Silence Therapeutics.

German science and technology group Merck KGaA, based in Darmstadt, signed a definitive agreement on 19 October 2026 to buy London-based Silence Therapeutics, a Nasdaq-listed developer of siRNA medicines, for USD 20.00 in cash per ADS through a UK scheme of arrangement. It was signed on 19 October 2026. It had not completed by 28 October 2026.

SigningDay 100

Signing 19 October 2026

Buyer
Merck KGaA ·Darmstadt, Germany
Target
Silence Therapeutics plc ·London, United Kingdom
Type
Acquisition
Announced
19 October 2026
Signed
19 October 2026
Value
about USD 1.3 billion
People
Not stated in the release
Last checked
28 October 2026

The people side in the United Kingdom

Related deals

Get the briefing

Deals into Europe lists public facts with their sources, checked every working day by Octagon Professionals International. Corrections go to info@octagon.nl and are made within one working day. How we track deals.

Enabling organisations to operate across borders with clarity, compliance, and trust.

All deals into Europe